Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Penumbra designs and manufactures neurovascular and peripheral vascular intervention devices, primarily mechanical thrombectomy systems for acute ischemic stroke and embolectomy catheters for pulmonary embolism. The company competes in high-growth interventional markets with proprietary aspiration technology (Penumbra System, Lightning Flash, Indigo System) and holds strong market share in stroke thrombectomy procedures performed in U.S. comprehensive stroke centers and internationally.
Penumbra sells single-use disposable devices and reusable capital equipment to hospitals and interventional labs. Revenue model is heavily weighted toward high-margin disposables consumed during procedures. Pricing power derives from clinical evidence demonstrating superior recanalization rates in stroke (ADAPT technique) and proprietary aspiration technology that differentiates from competitor stent retrievers. The company benefits from procedure volume growth as stroke center certifications expand globally and as peripheral vascular applications gain adoption. Gross margins of 63% reflect manufacturing scale in Alameda facility and premium pricing for differentiated technology.
U.S. neurovascular procedure volume growth rates, particularly mechanical thrombectomy adoption in primary stroke centers beyond comprehensive centers
International revenue acceleration, especially China market penetration and European hospital capital equipment cycles
Peripheral vascular segment growth trajectory, specifically Indigo System adoption for pulmonary embolism and deep vein thrombosis indications
Clinical trial readouts and FDA label expansions that broaden addressable patient populations
Gross margin trends reflecting manufacturing efficiency gains versus pricing pressure from hospital group purchasing organizations
Reimbursement pressure from CMS and commercial payers as thrombectomy procedures become standard of care, potentially compressing hospital budgets for devices
Regulatory pathway complexity for new device iterations requiring 510(k) clearances or PMA approvals, with FDA scrutiny on neurovascular safety increasing post-market surveillance requirements
Shift toward value-based care models where hospitals negotiate bundled payments, creating incentive to use lower-cost competitive devices
Stryker Neurovascular, Medtronic, and Johnson & Johnson hold significant market share in stroke thrombectomy with stent retriever technology and broader neurovascular portfolios including flow diversion
Boston Scientific and Inari Medical compete directly in peripheral vascular thrombectomy with alternative mechanical and pharmacomechanical approaches
Large medtech competitors possess greater sales force scale, installed base relationships, and ability to bundle products in hospital contracts
Current ratio of 6.73 and minimal debt indicate strong liquidity, but free cash flow of $0.1B on $1.2B revenue (1.1% FCF yield) reflects ongoing working capital investment and capex for manufacturing expansion
Operating margin of 0.8% provides limited buffer if revenue growth decelerates or gross margins compress, requiring careful expense management to avoid losses
low - Stroke and pulmonary embolism procedures are medically urgent and non-discretionary. Hospital capital equipment purchases show modest cyclicality during severe recessions when hospital systems defer investments, but disposable device volumes remain stable. Medicare and commercial insurance reimbursement provides revenue stability independent of GDP fluctuations. International growth may show sensitivity to healthcare spending cycles in emerging markets.
Rising rates create modest headwind through higher hospital cost of capital for equipment purchases and potential pressure on valuation multiples for high-growth medtech stocks trading at 10x sales. Company maintains minimal debt (0.16 D/E) so direct financing cost impact is negligible. Rate environment affects M&A capacity and competitive dynamics if larger medtech acquirers face higher financing costs.
Minimal - Revenue derived from hospitals with stable payment cycles. Accounts receivable risk is low given concentration among large U.S. hospital systems and government payers internationally. No meaningful exposure to consumer credit or commercial lending cycles.
growth - Investors focus on 12.9% revenue growth, large addressable market expansion in stroke and peripheral vascular intervention, and potential for margin expansion as company scales. Stock trades at 10x sales reflecting expectations for sustained double-digit growth and eventual operating margin expansion toward 20%+ medtech peer levels. Recent 25.7% one-year return and 34.7% six-month return indicate momentum investor participation. Negative EPS growth of -84.6% reflects investment phase prioritizing market share over profitability.
high - Medtech growth stocks at 10x sales with minimal profitability exhibit elevated volatility around clinical trial results, quarterly revenue beats/misses, and FDA regulatory decisions. Beta likely exceeds 1.2 given small-cap medtech characteristics and sensitivity to growth stock rotation. Stock susceptible to sharp moves on competitor product launches or reimbursement policy changes.